慧智基因股份有限公司
慧智基因股份有限公司在台灣及國際市場提供生殖醫學、產前及新生兒基因檢測服務。服務包括胚胎植入前染色體篩檢 (PGT-A)、非侵入性胚胎染色體篩檢 (niPGT-A)、胚胎植入前單基因檢測 (PGT-M)；產前檢測如非侵入性胎兒染色體檢測、晶片篩檢、唐氏症篩檢、子癇前症風險評估、脊髓性肌肉萎縮症及脆折症篩檢。亦提供新生兒聽損、癌症篩檢及罕見疾病基因檢測。公司成立於 2012 年，總部位於台灣台北市。
該股 RSI(6) 為 45.9，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。KD 指標中性（K=52.1）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | -2 | 0 | 0 | -2 |
| 08-07 | -2 | 0 | 0 | -2 |
| 08-06 | -2 | 0 | 0 | -2 |
| 08-05 | -2 | 0 | 0 | -2 |
| 08-03 | +3 | 0 | 0 | +3 |
| 07-31 | -3 | 0 | 0 | -3 |
| 07-30 | +1 | 0 | 0 | +1 |
| 07-29 | +2 | 0 | 0 | +2 |
| 07-28 | 0 | 0 | 0 | 0 |
| 07-27 | +2 | 0 | 0 | +2 |
| 07-23 | +6 | 0 | 0 | +6 |
| 07-22 | 0 | 0 | 0 | 0 |
| 07-20 | 0 | 0 | 0 | 0 |
| 07-14 | +1 | 0 | 0 | +1 |
| 07-13 | +2 | 0 | 0 | +2 |
| 07-08 | 0 | 0 | 0 | -1 |
| 07-06 | -3 | 0 | 0 | -3 |
| 07-02 | -1 | 0 | 0 | -1 |
| 07-01 | -7 | 0 | 0 | -7 |
| 06-30 | 0 | 0 | 0 | 0 |
| 06-29 | -2 | 0 | 0 | -3 |
| 06-26 | 0 | 0 | 0 | 0 |
| 06-25 | -5 | 0 | 0 | -5 |
| 06-24 | -7 | 0 | 0 | -8 |
| 06-23 | 0 | 0 | 0 | 0 |
| 06-22 | -1 | 0 | 0 | -1 |
| 06-18 | -3 | 0 | 0 | -3 |
| 06-17 | -1 | 0 | 0 | -1 |
| 06-16 | -3 | 0 | 0 | -3 |
| 06-15 | -6 | 0 | 0 | -6 |
| 06-12 | -3 | 0 | 0 | -3 |
| 06-10 | +2 | 0 | 0 | +2 |
| 06-09 | -4 | 0 | +1 | -3 |
| 06-08 | 0 | 0 | 0 | 0 |
| 06-05 | +4 | 0 | 0 | +4 |
| 06-04 | 0 | 0 | 0 | 0 |
| 06-03 | 0 | 0 | 0 | 0 |
| 06-02 | +1 | 0 | 0 | +1 |
| 06-01 | -1 | 0 | 0 | -1 |
| 05-29 | -1 | 0 | 0 | -1 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 3016 萬 | -12.2% | -9.1% |
| 2026/03 | 3437 萬 | +30.0% | +2.8% |
| 2026/02 | 2643 萬 | -20.1% | -15.7% |
| 2026/01 | 3308 萬 | -1.9% | +6.3% |
| 2025/12 | 3373 萬 | +9.3% | -3.4% |
| 2025/11 | 3086 萬 | -0.8% | -4.9% |
| 2025/10 | 3111 萬 | +3.7% | -13.8% |
| 2025/09 | 3001 萬 | -3.6% | -11.3% |
| 2025/08 | 3113 萬 | -3.5% | -17.8% |
| 2025/07 | 3227 萬 | -2.7% | -6.7% |
| 2025/06 | 3316 萬 | -3.4% | -19.8% |
| 2025/05 | 3434 萬 | - | -13.6% |